Isatuximab Affords the R/R Multiple Myeloma Setting a Tolerable New Alternative
Rachel Narozniak, MA
Published: Tuesday, Mar 31, 2020
Ken Shain, MD, PhD
The recent approval of isatuximab-irfc (Sarclisa) combined with pomalidomide (Pomalyst) and dexamethasone offers adults with multiple myeloma whose disease has progressed after standard therapy a tolerable new treatment option.
... to read the full story